Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain

British Journal of Pharmacology

Volumn 141, Issue 1, 2004, Pages 4-8

  Costa, B ^a   Colleoni, M ^b   Conti, S ^a   Trovato, A E ^a   Bianchi, M ^b   Sotgiu, M L ^c   Giagnoni, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

Endogenous cannabinoid system; Neuropathic pain; Nitric oxide system; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR AGONIST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; WIN 55 2122;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERALGESIA; MALE; MECHANICAL STIMULATION; NERVE LIGATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SCIATIC NERVE; STIMULUS RESPONSE; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; CANNABINOIDS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HEAT; HYPERALGESIA; INJECTIONS, SUBCUTANEOUS; MALE; MORPHOLINES; NAPHTHALENES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NOCICEPTORS; PAIN MEASUREMENT; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; SCIATIC NERVE; SCIATIC NEUROPATHY; TIME FACTORS;

EID: 1242296234     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705587     Document Type: Article

References (21)

1. BENNET, G.J. & XIE, Y.K. (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 33, 87-107.
2. BRIDGES, D., AHMAD, K. & RICE, A.S.C. (2001a). The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol., 133, 586-594.
3. BRIDGES, D., THOMPSON, S.W.N. & RICE, A.S.C. (2001b). Mechanisms of neuropathic pain. Br. J. Anaesth., 87, 12-26.
4. CHAPMAN, V. (2001). Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology, 41, 870-877.
5. COMPTON, D.R., RICE, K.C., DE COSTA, B.R., RAZDAN, R.K., MELVIN, L.S., JOHNSON, M.R. & MARTIN, B.R. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther., 265, 218-226.
6. FOLEY, K.M. (2003). Opioids and chronic neuropathic pain. N. Engl. J. Med., 348, 1279-1281.
7. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain, 92, 91-100.
8. HARGREAVES, K.M., DUBNER, R., BROWN, S., FLORES, C. & JORIS, J. (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain, 32, 77-88.
9. HERZBERG, U., ELIAV, E., BENNETT, G.J. & KOPIN, I.J. (1997). The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett., 221, 157-160.
10. IBRAHIM, M.M., DENG, H., ZWONOK, A., COCKAYNE, D.A., KWAN, J., MATA, H.P., VANDERAH, T.W., LAI, J., PORRECA, F., MAKRIYANNIS, A. & MALAN JR, T.P. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A., 100, 10529-10533.
11. LEVY, D. & ZOCHODNE, D.W. (1998). Local nitric oxide synthase activity in a model of neuropathic pain. Eur. J. Neurosci., 10, 1846-1855.
12. LUO, Z.D., CHAPLAN, S.R., SCOTT, B.P., CIZKOVA, D., CALCUTT, N.A. & YAKSH, T.L. (1999). Neuronal nitric oxide synthase mRNA upregulation in rat sensory neurons after spinal nerve ligation: lack of a role in allodynia development. J. Neurosci., 19, 9201-9208.
13. MA, W. & EISENACH. J.C. (2002). Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur. J. Neurosci., 15, 1037-1047.
14. MAO, J., PRICE, D.D., LU, J., KENISTON, L. & MAYER, D.J. (2000). Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett., 280, 13-16.
15. MISKO, T.P., SCHILLING, R.J., SALVEMINI, D., MOORE, W.M. & CURRIE, M.G. (1993). A fluorimetric assay for the measurement of nitrite in biological samples. Anal. Biochem., 214, 11-16.
16. NACKLEY, A.G., SUPLITA, R.L. & HOHMANN, A.G. (2003). A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 117, 659-670.
17. PERTWEE, R.G. (2001). Cannabinoid receptors and pain. Prog. Neurobiol., 63, 569-611.
18. QI, W.N., YAN, Z.Q., WHANG, P.G., ZHOU, Q., CHEN, L.E., SEABER, A.V., STAMLER, J.S. & URBANIAK, J.R. (2001). Gene and protein expressions of nitric oxide synthases in ischemia-reperfused peripheral nerve of the rat. Am. J. Physiol. Cell Physiol. 281, C849-C856.
19. 1 receptor upregulation in a rat model of chronic neuropathic pain. Eur. J. Pharmacol., 415, R5-R7.
20. ZHANG, J., HOFFERT, C., VU, H.K., GROBLEWSKI, T., AHMAD, S. & O'DONNEL, D. (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci., 17, 2750-2754.
21. ZIMMERMANN, M. (1983). Ethical guidelines for investigation of experimental pain in conscious animals. Pain, 16, 109-110.